Literature DB >> 15482185

Coartemether (artemether and lumefantrine): an oral antimalarial drug.

Walther H Wernsdorfer1.   

Abstract

Coartemether (Riamet, Coartem, Novartis), a tablet formulation of artemether and lumefantrine, is a well-tolerated, fast-acting and effective blood schizontocidal drug that serves primarily in the treatment of uncomplicated falciparum malaria that is resistant to other antimalarials. Initial clinical-parasitological response relies mainly on the artemether component, while lumefantrine effects radical cure. The absorption of lumefantrine is poor during the fasting state, the normal condition in acutely ill malaria patients, but with return to normal diet it becomes adequate. This highlights the need for an appropriate adjustment of the dose regimen. In the area where Plasmodium falciparum shows the highest degree of multidrug resistance worldwide, the best results (99% cure) were obtained with a six-dose regimen given over 5 days. Extensive cardiological investigations have demonstrated the high cardiac safety of coartemether.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482185     DOI: 10.1586/14787210.2.2.181

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  13 in total

1.  Current challenges in travelers' malaria.

Authors:  Patricia Schlagenhauf; Eskild Petersen
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

2.  In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in Plasmodium vivax.

Authors:  Leila Kyavar; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Gunther Wernsdorfer; Jeeraphat Sirichaisinthop; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

Review 3.  Modern malaria chemoprophylaxis.

Authors:  G Dennis Shanks; Michael D Edstein
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.

Authors:  Peter Starzengruber; Gunther Wernsdorfer; Maria Parizek; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

5.  Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum.

Authors:  Maria Parizek; Jeeraphat Sirichaisinthop; Gunther Wernsdorfer; Harald Noedl; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

6.  Pharmacodynamic interaction between monodesbutyl-benflumetol and artemisinin as well as proguanil in Plasmodium falciparum in vitro.

Authors:  Jens Raffelsberger; Gunther Wernsdorfer; Jeeraphat Sirichaisinthop; Herwig Kollaritsch; Kanungnit Congpuong; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

7.  Interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum in vitro.

Authors:  Peter Starzengruber; Herwig Kollaritsch; Jeeraphat Sirichaisinthop; Gunther Wernsdorfer; Kanungnit Congpuong; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

8.  Intravenous pharmacokinetics, oral bioavailability, dose proportionality and in situ permeability of anti-malarial lumefantrine in rats.

Authors:  Sheelendra P Singh; Kanumuri S R Raju; Asad Nafis; Sunil K Puri; Girish K Jain
Journal:  Malar J       Date:  2011-10-10       Impact factor: 2.979

9.  New perspectives on chinese herbal medicine (zhong-yao) research and development.

Authors:  Si-Yuan Pan; Si-Bao Chen; Hong-Guang Dong; Zhi-Ling Yu; Ji-Cui Dong; Zhi-Xian Long; Wang-Fun Fong; Yi-Fan Han; Kam-Ming Ko
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-10       Impact factor: 2.629

Review 10.  Management of imported malaria in Europe.

Authors:  Helena H Askling; Fabrice Bruneel; Gerd Burchard; Francesco Castelli; Peter L Chiodini; Martin P Grobusch; Rogelio Lopez-Vélez; Margaret Paul; Eskild Petersen; Corneliu Popescu; Michael Ramharter; Patricia Schlagenhauf
Journal:  Malar J       Date:  2012-09-17       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.